1. Home
  2. MATH vs IMUX Comparison

MATH vs IMUX Comparison

Compare MATH & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Metalpha Technology Holding Limited

MATH

Metalpha Technology Holding Limited

HOLD

Current Price

$1.19

Market Cap

82.9M

Sector

Finance

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$1.04

Market Cap

75.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MATH
IMUX
Founded
2015
2016
Country
Hong Kong
United States
Employees
N/A
66
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
82.9M
75.2M
IPO Year
2016
2013

Fundamental Metrics

Financial Performance
Metric
MATH
IMUX
Price
$1.19
$1.04
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$5.00
AVG Volume (30 Days)
91.0K
3.8M
Earning Date
01-01-0001
05-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
38.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.10
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.16
$0.51
52 Week High
$4.17
$1.35

Technical Indicators

Market Signals
Indicator
MATH
IMUX
Relative Strength Index (RSI) 30.56 70.56
Support Level N/A $0.96
Resistance Level $4.04 $1.17
Average True Range (ATR) 0.10 0.11
MACD 0.02 0.01
Stochastic Oscillator 14.29 73.77

Price Performance

Historical Comparison
MATH
IMUX

About MATH Metalpha Technology Holding Limited

Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and generates majority of its revenue from Hong Kong.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Share on Social Networks: